NYSE$PCRX
Pacira BioSciences Inc. · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Pacira had a pivotal year due to the acquisition of Flexion Therapeutics combined with record EXPAREL sales, entering 2022 in the strongest financial position in the company’s history.
Pacira BioSciences reported a 22% increase in total revenues for Q4 2021, reaching $159.2 million compared to $131.0 million in Q4 2020. EXPAREL net product sales increased by 12% to $139.9 million. The company experienced a GAAP net loss of $5.1 million, or $0.12 per share, but adjusted EBITDA increased by 61% to $69.3 million.
- Total revenues increased by 22% to $159.2 million compared to Q4 2020.
- EXPAREL net product sales increased by 12% to $139.9 million compared to Q4 2020.
- ZILRETTA net product sales were $12.7 million after the acquisition of Flexion Therapeutics in November 2021.
- Adjusted EBITDA increased by 61% to $69.3 million compared to Q4 2020.
Headline financials
Revenue & EPS history
Pacira · Revenue · Quarterly
$159M
Revenue by segment
Pacira · $158M total across 3 segments · Q4 2021
- EXPAREL$140M+11.6%88.8%
- ZILRETTA$12.7M—8.1%
- iovera°$4.9M+102.0%3.1%
Forward guidance
Pacira is providing full-year 2022 operating expense guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.9%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-1.2%
Avg return
30 days after
64%
37 / 58 earnings
Positive
+23.7%
Q3 2015
Best reaction
-16.2%
Q1 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.4% | -1.4% | -7.7% | |
| Q4 2025 | -3.2% | +1.2% | +1.3% | |
| Q3 2025 | +4.6% | +13.1% | +13.7% | |
| Q1 2025 | +0.9% | -1.8% | +4.3% | |
| Q4 2024 | -5.2% | -7.4% | -1.9% | |
| Q3 2024 | +2.4% | +1.3% | +11.5% | |
| Q2 2024 | +1.4% | +4.4% | -24.6% | |
| Q1 2024 | +11.9% | +11.0% | +9.9% | |
| Q4 2023 | -3.5% | -1.6% | -2.3% | |
| Q3 2023 | +9.6% | +7.0% | -1.8% | |
| Q2 2023 | +7.6% | +5.9% | -1.3% | |
| Q1 2023 | -7.1% | -9.0% | -15.8% | |
| Q4 2022 | +5.9% | +2.7% | -1.9% | |
| Q3 2022 | -2.2% | -1.2% | -7.3% | |
| Q2 2022 | -3.5% | -1.0% | -4.4% | |
| Q1 2022 | +2.8% | +6.1% | -6.9% | |
| Q4 2021 | +7.3% | +2.0% | -16.5% | |
| Q3 2021 | -2.0% | -3.2% | -4.5% | |
| Q2 2021 | -6.1% | -3.7% | -7.2% | |
| Q1 2021 | +1.8% | +2.2% | -2.8% | |
| Q4 2020 | -6.7% | +0.7% | -6.3% | |
| Q3 2020 | +0.4% | +1.8% | +22.5% | |
| Q2 2020 | +4.0% | +6.9% | +7.9% | |
| Q1 2020 | +0.8% | +3.0% | +16.3% | |
| Q4 2019 | -4.4% | -8.7% | -38.0% | |
| Q3 2019 | +5.8% | +3.0% | +10.3% | |
| Q2 2019 | -3.1% | -8.4% | -18.1% | |
| Q1 2019 | +1.2% | +0.1% | -5.9% | |
| Q4 2018 | +3.8% | -3.8% | -6.3% | |
| Q3 2018 | +2.9% | +1.6% | -1.1% | |
| Q2 2018 | +11.3% | +10.2% | +16.1% | |
| Q1 2018 | -1.2% | -4.6% | -1.1% | |
| Q4 2017 | +4.8% | +2.2% | -0.2% | |
| Q3 2017 | +14.6% | +22.0% | +27.8% | |
| Q2 2017 | -3.4% | -6.6% | -2.9% | |
| Q1 2017 | +4.5% | +6.6% | -3.7% | |
| Q4 2016 | +13.0% | +10.9% | +4.3% | |
| Q3 2016 | -4.7% | -3.0% | -5.9% | |
| Q2 2016 | +16.1% | +21.1% | +4.1% | |
| Q1 2016 | -4.7% | — | — | |
| Q4 2015 | -6.0% | — | — | |
| Q3 2015 | +23.7% | — | — | |
| Q2 2015 | +13.2% | — | — | |
| Q1 2015 | -16.2% | — | — | |
| Q4 2014 | +1.0% | — | — | |
| Q3 2014 | -12.3% | — | — | |
| Q2 2014 | +9.2% | — | — | |
| Q1 2014 | +6.4% | — | — | |
| Q4 2013 | +6.4% | — | — | |
| Q3 2013 | +6.1% | — | — | |
| Q2 2013 | -0.1% | — | — | |
| Q1 2013 | +2.0% | — | — | |
| Q3 2012 | +0.2% | — | — | |
| Q2 2012 | +4.0% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q3 2011 | -9.7% | — | — | |
| Q2 2011 | +1.9% | — | — | |
| Q1 2011 | -0.1% | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro